Lapmahapaisan Saowaphak, Chinachoti Thitima, Maisat Wiriya, Kleebchan Natthawat, Chatsiricharoenkul Somruedee, Charoencholvanich Keerati, Rungwattanakij Paweenus, Sakulpacharoen Nuchanat, Sri-In Jureeporn
J Med Assoc Thai. 2014 Jul;97(7):724-9.
To determine the plasma concentrations of bupivacaine and toxicity after periarticular injection (PAI) combined with spinal anesthesia and femoral nerve block (FNB).
Forty-three patients scheduled for unilateral total knee arthroplasty (TKA) were enrolled in the prospective observational study. The dose of bupivacaine for spinal anesthesia was adjusted by the attending anesthesiologist. The single-shot femoral nerve block (FNB) and periarticular injection (PAI) were performed with 20 ml of 0.5% bupivacaine and 20 ml of 0.25% bupivacaine respectively. Venous blood samples from antecubital vein were collected at 60 minutes after femoral nerve block and at the time before periarticular injection, then at 15, 30, 45, and 60 minutes afterwards. Plasma bupivacaine concentrations were analyzed, using a high performance liquid chromatography with tandem mass spectrometry.
Ten males and 32 females, ASA I-II were included. The highest median plasma concentration was 586.22 ng/ml (min = 245.39, max = 1,614.36) at 45 minutes after periarticular injection. The maximum plasma bupivacaine concentration was 1,709.71 ng/ml at 60 minutes after periarticular injection. No clinical toxicity was encountered
The plasma concentration of bupivacaine in patients performed periarticular injection with 20 ml of 0.25% bupivacaine after spinal anesthesia and single-shot femoral nerve block with 20 ml of 0.5% bupivacaine is below the plasma toxic level.
确定关节周围注射(PAI)联合脊髓麻醉和股神经阻滞(FNB)后布比卡因的血浆浓度及毒性。
43例计划行单侧全膝关节置换术(TKA)的患者纳入前瞻性观察研究。脊髓麻醉的布比卡因剂量由主治麻醉医师调整。单次股神经阻滞(FNB)和关节周围注射(PAI)分别使用20 ml 0.5%布比卡因和20 ml 0.25%布比卡因进行。在股神经阻滞后60分钟、关节周围注射前、注射后15、30、45和60分钟采集肘前静脉血样。采用高效液相色谱串联质谱法分析血浆布比卡因浓度。
纳入10例男性和32例女性,ASA分级为I-II级。关节周围注射后45分钟时,血浆浓度中位数最高,为586.22 ng/ml(最小值 = 245.39,最大值 = 1,614.36)。关节周围注射后60分钟时,血浆布比卡因最大浓度为1,709.71 ng/ml。未出现临床毒性。
在脊髓麻醉后采用20 ml 0.25%布比卡因进行关节周围注射以及采用20 ml 0.5%布比卡因进行单次股神经阻滞后,患者血浆布比卡因浓度低于血浆中毒水平。